Huang Tie-Jun, Huang Bi-Jun, Liang Qi-Wan, Huang Chu-Wen, Fang Yan
Research Department, Cancer Center, Sun Yat-Sen University, Guangzhou 510060, China.
Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):62-8.
Molecular cytogenetics of oncogene HER-2 amplification in primary hepatocellular carcinoma (HCC) is still unknown. The aim of this study was to investigate the frequency of HER-2 oncogene amplification in primary HCC and its relations to clinicopathological parameters and prognosis.
Forty-two surgical samples from patients with primary HCC were detected for their HER-2 oncogene amplification. The number of chromosome 17 and their ratio were tested by dual fluorescence in situ hybridization (FISH) technique, and then the correlations between HER-2 amplification, clinicopathological characteristics and prognosis were analyzed statistically.
HER-2 oncogene amplification was detected in 9 (21.4%) of the 42 primary HCCs, including 4 patients with high copy (HC) (9.5%) and 5 patients with low copy (LC) (11.9%). HER-2 amplification was associated significantly with tumor size and postoperative survival time of HCC patients (P<0.05), and the presence of HER-2 gene amplification was correlated with postoperative relapse (P=0.257), but not related to sex, age, AFP level, HBV infection, histopathological grading and clinical staging of HCC patients (P>0.05). The HER-2 oncogene copy was examined in 31 (73.8%) of the 42 primary HCCs, consisting of 9 patients with HER-2 amplification (21.4%) and 22 patients with aneuploidy (52.4%). No significant relations were observed between the HER-2 oncogene copy, patient sex, tumor size, histopathological grading, clinical staging, postoperative relapse and survival time (P>0.05); but the HER-2 oncogene copy was correlated significantly to age, AFP level and HBV infection (P<0.05).
There are a lower frequency of HER-2 oncogene amplification and a higher frequency of chromosome 17 aneuploidy in primary HCC. HER-2 oncogene amplification may be involved in the development and progression of large HCC in some patients, and seems to be a valuably independent prognostic factor predicting the recurrence and poor survival in patients with large HCC.
原发性肝细胞癌（HCC）中癌基因HER-2扩增的分子细胞遗传学情况仍不清楚。本研究旨在调查原发性HCC中HER-2癌基因扩增的频率及其与临床病理参数和预后的关系。
对42例原发性HCC患者的手术样本进行HER-2癌基因扩增检测。采用双色荧光原位杂交（FISH）技术检测17号染色体数目及其比例，然后对HER-2扩增、临床病理特征与预后之间的相关性进行统计学分析。
42例原发性HCC中9例（21.4%）检测到HER-2癌基因扩增，其中4例为高拷贝（HC）（9.5%），5例为低拷贝（LC）（11.9%）。HER-2扩增与HCC患者的肿瘤大小和术后生存时间显著相关（P<0.05），HER-2基因扩增的存在与术后复发相关（P=0.257），但与HCC患者的性别、年龄、甲胎蛋白水平、乙肝病毒感染、组织病理学分级和临床分期无关（P>0.05）。42例原发性HCC中的31例（73.8%）检测了HER-2癌基因拷贝数，其中9例HER-2扩增（21.4%），22例非整倍体（52.4%）。未观察到HER-2癌基因拷贝数与患者性别、肿瘤大小、组织病理学分级、临床分期、术后复发及生存时间之间存在显著关系（P>0.05）；但HER-2癌基因拷贝数与年龄、甲胎蛋白水平和乙肝病毒感染显著相关（P<0.05）。
原发性HCC中HER-2癌基因扩增频率较低，17号染色体非整倍体频率较高。HER-2癌基因扩增可能参与了部分大HCC患者的发生发展过程，似乎是预测大HCC患者复发和不良生存的一个有价值的独立预后因素。
